Treatment of lipid disorders after stroke

Area of Science:

• Cardiovascular Medicine
• Neurology
• Pharmacology

Background:

• Lipid disorder therapy is proven for coronary heart disease (CHD) prevention.
• No studies have specifically evaluated lipid therapy for stroke risk reduction.
• Observational studies show no link between lipid disorders and stroke, but recent trials suggest otherwise.

Purpose of the Study:

• To review the current evidence on lipid therapy's role in stroke prevention.
• To discuss the implications of recent findings for clinical practice.
• To highlight the need for dedicated stroke prevention trials using lipid-modifying drugs.

Main Methods:

• Review of established guidelines for lipid disorder management.
• Analysis of recently completed clinical trials in patients at risk for CHD.
• Evaluation of observational cohort studies on lipids and stroke.

Main Results:

• Statins and fibric acid derivatives reduce myocardial infarction and death.
• These lipid-lowering agents also demonstrated a reduction in brain infarction and transient ischemic attacks.
• Lipid drugs are generally well-tolerated with low complication rates.

Conclusions:

• Stroke patients with dyslipidemia and a history of CHD should receive lipid treatment.
• For stroke patients with dyslipidemia but no CHD history, primary prevention of heart disease is recommended.
• Further clinical trials are essential to confirm lipid therapy's efficacy in reducing stroke risk.